Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.

This week, federal health officials finalized a set of rules tied to the last leg of the 2022 Inflation Reduction Act. The ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

Insulin: In 2019, employer plan participants who used insulin spent an average of $82 per month out-of-pocket on their ...